Targeting hypoxia at the forefront of anticancer immune responses
Authors:
- 2 December 2014
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 3 (12) , e954463
Abstract
Hypoxia influences immune checkpoint receptors and their respective ligands. In support, we recently demonstrated that hypoxia selectively upregulates programmed cell death ligand 1 (PD-L1) on myeloid-derived suppressor cells (MDSCs) via hypoxia inducible factor 1 α (HIF-1α) binding to a hypoxia-response element (HRE) in the PD-L1 proximal promoter. Furthermore, blockade of PD-L1 under hypoxic conditions enhanced MDSC-mediated T-cell activation by attenuating MDSC secretion of IL-6 and IL-10.Keywords
This publication has 10 references indexed in Scilit:
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activationJournal of Experimental Medicine, 2014
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer CellsCancer Research, 2014
- Cutting Edge: Hypoxia-Induced Nanog Favors the Intratumoral Infiltration of Regulatory T Cells and Macrophages via Direct Regulation of TGF-β1The Journal of Immunology, 2013
- Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigenNature Immunology, 2013
- Hypoxia-induced autophagyAutophagy, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- Cytotoxic T cells – Stroma interactionsBulletin du Cancer, 2011
- The Cooperative Induction of Hypoxia-Inducible Factor-1α and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell LysisThe Journal of Immunology, 2009
- Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunityNature Medicine, 2003